Xinghu Technology announced that with the approval of the China Securities Regulatory Commission, the company purchased 99.22% of Yipin Biotech's shares from Guangxin Group and others, and completed the registration of additional shares on December 6, 2022. Counterparties such as Guangxin Group have made promises for the restricted stock lockdown period. Yipin Biotech's performance promise for 2022 to 2024 has been fulfilled, and Guangxin Group has strictly fulfilled its promises. The shareholder applying to lift the share sales restrictions is Guangxin Group. 405,703,292 restricted shares will be listed and circulated on August 4, 2026, accounting for 24.42% of the company's total share capital.

Xinghu Technology announced that with the approval of the China Securities Regulatory Commission, the company purchased 99.22% of Yipin Biotech's shares from Guangxin Group and others, and completed the registration of additional shares on December 6, 2022. Counterparties such as Guangxin Group have made promises for the restricted stock lockdown period. Yipin Biotech's performance promise for 2022 to 2024 has been fulfilled, and Guangxin Group has strictly fulfilled its promises. The shareholder applying to lift the share sales restrictions is Guangxin Group. 405,703,292 restricted shares will be listed and circulated on August 4, 2026, accounting for 24.42% of the company's total share capital.